Categories: HealthcareNews

Pennant Announces Second Quarter 2023 Earnings Release and Call

EAGLE, Idaho, July 28, 2023 (GLOBE NEWSWIRE) — The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it expects to issue its second quarter 2023 financial results on Tuesday, August 8, 2023.

Pennant invites current and prospective investors to tune into a live webcast to be held the following day, Wednesday, August 9, 2023, at 10:00 a.m. Mountain Time (12:00 p.m. Eastern Time), during which Pennant’s management will discuss its second quarter 2023 results.

To listen to the webcast, or to view any financial or other statistical information required by SEC Regulation G, please visit the Investor Relations section of our website at http://investor.pennantgroup.com. The webcast will be recorded, and will be available for replay via the website until August 8, 2024.

About Pennant

The Pennant Group, Inc. is a holding company of independent operating subsidiaries that provide healthcare services through 98 home health and hospice agencies and 51 senior living communities located throughout Arizona, California, Colorado, Idaho, Iowa, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. Each of these businesses is operated by a separate, independent operating subsidiary that has its own management, employees and assets. References herein to the consolidated “company” and “its” assets and activities, as well as the use of the terms “we,” “us,” “its” and similar verbiage, are not meant to imply that The Pennant Group, Inc. has direct operating assets, employees or revenue, or that any of the home health and hospice businesses, senior living communities or the Service Center are operated by the same entity. More information about Pennant is available at www.pennantgroup.com.

Contact

The Pennant Group, Inc.
(208) 506-6100
ir@pennantservices.com

SOURCE: The Pennant Group, Inc.

Staff

Recent Posts

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers…

15 minutes ago

CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026

CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an…

11 hours ago

TempraMed Closes C$2.5 Million Fully Subscribed Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

14 hours ago

TruuCONNECT NJ Statewide Digital Hub Empowers Users to Find Verified, Local Community Resources and Support – Anonymously and in Real Time

MOUNT LAUREL, N.J., Jan. 12, 2026 /PRNewswire/ -- Born out of a partnership between the…

14 hours ago

Nuvo Unveils Large-Scale AI-Ready Pregnancy Dataset Built on Real-World Maternal and Fetal Physiology

Unique longitudinal dataset combining native fetal and maternal ECG with phonocardiography supports deeper insights into…

14 hours ago

Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer’s Disease Research

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision…

14 hours ago